SEARCH:   Advanced

Blood, 15 April 2007, Vol. 109, No. 8, pp. 3207-3213. Prepublished online as a Blood First Edition Paper on December 21, 2006; DOI 10.1182/blood-2006-09-046888. This Article Full Text (PDF) All Versions of this Article: blood-2006-09-046888v1 109/8/3207    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Cortes, J. Articles by Baccarani, M. Search for Related Content PubMed PubMed Citation Articles by Cortes, J. Articles by Baccarani, M. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted September 13, 2006 Accepted December 4, 2006 Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis Jorge Cortes*, Philippe Rousselot, Dong-Wook Kim, Ellen Ritchie, Nelson Hamerschlak, Steven Coutre, Andreas Hochhaus, Francois Guilhot, Giuseppe Saglio, Jane Apperley, Oliver Ottmann, Neil Shah, Philipp Erben, Susan Branford, Prasheen Agarwal, Ashwin Gollerkeri, and Michele Baccarani MD Anderson Cancer Center, Houston, Texas, USA Hospital Saint Louis, Centre d'Investigation Clinique, Paris Cedex, France Uijeongbu St. Mary's Hospital, Kyunggi-Do, Republic of Korea Weill Medical College - Cornell University, New York Presbyterian Hospital, New York, New York, USA Hospital Israelita Albert Einstein, Sao Paulo, Brazil Stanford University School of Medicine, Stanford, California, USA Medizinische Fakultat Mannheim, Universitat Heidelberg, Mannheim, Germany Hopital Jean Bernard, Poitiers, France Azienda Ospedaliera S. Luigi, Orbassano, Italy Hammersmith Hospital, London, UK Johann Wolfgang Goethe Universitat, Frankfurt-am-Main, Germany University College of Los Angeles, Los Angeles, California, USA Division of Hematology, Institute of Medical and Veterinary Science, Adelaide, Australia Bristol-Myers Squibb, Wallingford, Connecticut, USA Istituto di Ematologica E Oncologica Medica, Policlinico S Orsola, Bologna, Italy * Corresponding author; email: jcortes{at}mdanderson.org. The prognosis for patients with chronic myeloid leukemia (CML) in myeloid or lymphoid blast crisis (MBC or LBC) remains poor. While imatinib can induce responses in a subset of these patients, resistance to this drug develops rapidly. Dasatinib is a novel, oral, multi-targeted kinase inhibitor of BCR-ABL and SRC family kinases. Following promising Phase-I results, we report results of Phase-II clinical trials of dasatinib in patients with imatinib-resistant or intolerant blast-crisis CML (MBC: n=74; LBC: n=42). At 8 months' follow-up, dasatinib induced major hematologic responses (MaHR) in 34% and 31% of MBC- and LBC-CML patients, and major cytogenetic responses (MCyR) in 31% and 50% of these patients, respectively. The majority (86%) of these MCyR were complete cytogenetic responses (CCyR). Responses were both rapid and durable: 88% and 46% of MBC- and LBC-CML patients achieving MaHR had not progressed at 8 months' follow-up. Response rates were similar in patients with and without BCR-ABL mutations known to confer resistance to imatinib. Dasatinib was well tolerated. Non-hematologic side effects were mild-to-moderate. Cytopenias were common and could be managed by dose modification. Dasatinib is highly active, producing hematologic and cytogenetic responses in a significant number of patients with imatinib-resistant or -intolerant MBC- and LBC-CML. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Unraveling CML phase by phase John Goldman Blood 2007 109: 3128. [Full Text] [PDF] This article has been cited by other articles: G. D. Demetri, P. Lo Russo, I. R.J. MacPherson, D. Wang, J. A. Morgan, V. G. Brunton, P. Paliwal, S. Agrawal, M. Voi, and T.R. J. Evans Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors Clin. Cancer Res., October 1, 2009; 15(19): 6232 - 6240. [Abstract] [Full Text] [PDF] Y. Chen, S. Agarwal, N. M. Shaik, C. Chen, Z. Yang, and W. F. Elmquist P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib J. Pharmacol. Exp. Ther., September 1, 2009; 330(3): 956 - 963. [Abstract] [Full Text] [PDF] J. F. Apperley, J. E. Cortes, D.-W. Kim, L. Roy, G. J. Roboz, G. Rosti, E. O. Bullorsky, E. Abruzzese, A. Hochhaus, D. Heim, et al. Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial J. Clin. Oncol., July 20, 2009; 27(21): 3472 - 3479. [Abstract] [Full Text] [PDF] H. Kantarjian, J. Cortes, D.-W. Kim, P. Dorlhiac-Llacer, R. Pasquini, J. DiPersio, M. C. Muller, J. P. Radich, H. J. Khoury, N. Khoroshko, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up Blood, June 18, 2009; 113(25): 6322 - 6329. [Abstract] [Full Text] [PDF] T. Eley, F. R. Luo, S. Agrawal, A. Sanil, J. Manning, T. Li, A. Blackwood-Chirchir, and R. Bertz Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects J. Clin. Pharmacol., June 1, 2009; 49(6): 700 - 709. [Abstract] [Full Text] [PDF] W. A. Messersmith, N.V. Rajeshkumar, A. C. Tan, X. F. Wang, V. Diesl, S. E. Choe, M. Follettie, C. Coughlin, F. Boschelli, E. Garcia-Garcia, et al. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts Mol. Cancer Ther., June 1, 2009; 8(6): 1484 - 1493. [Abstract] [Full Text] [PDF] C. Fava, H. M. Kantarjian, E. Jabbour, S. O'Brien, N. Jain, M. B. Rios, G. Garcia-Manero, F. Ravandi, S. Verstovsek, G. Borthakur, et al. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase Blood, May 21, 2009; 113(21): 5058 - 5063. [Abstract] [Full Text] [PDF] T. Tyler Once-Daily Dasatinib for Treatment of Patients with Chronic Myeloid Leukemia Ann. Pharmacother., May 1, 2009; 43(5): 920 - 927. [Abstract] [Full Text] [PDF] J. S. Lagas, R. A.B. van Waterschoot, V. A.C.J. van Tilburg, M. J. Hillebrand, N. Lankheet, H. Rosing, J. H. Beijnen, and A. H. Schinkel Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment Clin. Cancer Res., April 1, 2009; 15(7): 2344 - 2351. [Abstract] [Full Text] [PDF] S.-F. Wong Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia Journal of Oncology Pharmacy Practice, March 1, 2009; 15(1): 17 - 27. [Abstract] [PDF] E. Jabbour, J. E. Cortes, and H. M. Kantarjian Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy? Mayo Clin. Proc., February 1, 2009; 84(2): 161 - 169. [Abstract] [Full Text] [PDF] T. O'Hare and M. W. Deininger Toward a Cure For Chronic Myeloid Leukemia Clin. Cancer Res., December 15, 2008; 14(24): 7971 - 7974. [Full Text] [PDF] B. J. Druker Translation of the Philadelphia chromosome into therapy for CML Blood, December 15, 2008; 112(13): 4808 - 4817. [Abstract] [Full Text] [PDF] F. Palandri, F. Castagnetti, N. Testoni, S. Luatti, G. Marzocchi, S. Bassi, M. Breccia, G. Alimena, E. Pungolino, G. Rege-Cambrin, et al. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up Haematologica, December 1, 2008; 93(12): 1792 - 1796. [Abstract] [Full Text] [PDF] G. Dai, M. Pfister, A. Blackwood-Chirchir, and A. Roy Importance of Characterizing Determinants of Variability in Exposure: Application to Dasatinib in Subjects With Chronic Myeloid Leukemia J. Clin. Pharmacol., November 1, 2008; 48(11): 1254 - 1269. [Abstract] [Full Text] [PDF] A. Giannoudis, A. Davies, C. M. Lucas, R. J. Harris, M. Pirmohamed, and R. E. Clark Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia Blood, October 15, 2008; 112(8): 3348 - 3354. [Abstract] [Full Text] [PDF] K. Porkka, P. Koskenvesa, T. Lundan, J. Rimpilainen, S. Mustjoki, R. Smykla, R. Wild, R. Luo, M. Arnan, B. Brethon, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia Blood, August 15, 2008; 112(4): 1005 - 1012. [Abstract] [Full Text] [PDF] A. Fabarius, M. Giehl, B. Rebacz, A. Kramer, O. Frank, C. Haferlach, P. Duesberg, R. Hehlmann, W. Seifarth, and A. Hochhaus Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib Haematologica, August 1, 2008; 93(8): 1145 - 1154. [Abstract] [Full Text] [PDF] B. Hackanson, H. Becker, T. Berg, M. Binder, C. Dierks, J. Duque-Afonso, M. D. Lairmore, H. S. Schafer, M. Schnitzler, R. Zeiser, et al. XXIII International Association for Comparative Research on Leukemia and Related Diseases Symposium: from Molecular Pathogenesis to Targeted Therapy in Leukemia and Solid Tumors Cancer Res., July 15, 2008; 68(14): 5512 - 5518. [Full Text] [PDF] J. Wu, F. Meng, L.-Y. Kong, Z. Peng, Y. Ying, W. G. Bornmann, B. G. Darnay, B. Lamothe, H. Sun, M. Talpaz, et al. Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase J Natl Cancer Inst, July 2, 2008; 100(13): 926 - 939. [Abstract] [Full Text] [PDF] N. P. Shah, H. M. Kantarjian, D.-W. Kim, D. Rea, P. E. Dorlhiac-Llacer, J. H. Milone, J. Vela-Ojeda, R. T. Silver, H. J. Khoury, A. Charbonnier, et al. Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia J. Clin. Oncol., July 1, 2008; 26(19): 3204 - 3212. [Abstract] [Full Text] [PDF] G. Giaccone and P. A. Zucali Src as a potential therapeutic target in non-small-cell lung cancer Ann. Onc., July 1, 2008; 19(7): 1219 - 1223. [Abstract] [Full Text] [PDF] S. Verstovsek, A. Tefferi, J. Cortes, S. O'Brien, G. Garcia-Manero, A. Pardanani, C. Akin, S. Faderl, T. Manshouri, D. Thomas, et al. Phase II Study of Dasatinib in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis Clin. Cancer Res., June 15, 2008; 14(12): 3906 - 3915. [Abstract] [Full Text] [PDF] R. Weichsel, C. Dix, L. Wooldridge, M. Clement, A. Fenton-May, A. K. Sewell, J. Zezula, E. Greiner, E. Gostick, D. A. Price, et al. Profound Inhibition of Antigen-Specific T-Cell Effector Functions by Dasatinib Clin. Cancer Res., April 15, 2008; 14(8): 2484 - 2491. [Abstract] [Full Text] [PDF] L. K. Kenealy, C. B. Christenson, and C. B. Williams Current Therapies for Chronic Myeloid Leukemia Journal of Pharmacy Practice, April 1, 2008; 21(2): 116 - 125. [Abstract] [PDF] M. Kneidinger, U. Schmidt, U. Rix, K. V. Gleixner, A. Vales, C. Baumgartner, C. Lupinek, M. Weghofer, K. L. Bennett, H. Herrmann, et al. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils Blood, March 15, 2008; 111(6): 3097 - 3107. [Abstract] [Full Text] [PDF] D. S. Ritchie, M. McBean, D. A Westerman, S. Kovalenko, J. F. Seymour, and A. Dobrovic Complete molecular response of e6a2 BCR-ABL-positive acute myeloid leukemia to imatinib then dasatinib Blood, March 1, 2008; 111(5): 2896 - 2898. [Abstract] [Full Text] [PDF] H. M Marshall and J. M Hammond Treatment Options in Imatinib-Resistant Chronic Myelogenous Leukemia Ann. Pharmacother., February 1, 2008; 42(2): 259 - 264. [Abstract] [Full Text] [PDF] A. E. Schade, G. L. Schieven, R. Townsend, A. M. Jankowska, V. Susulic, R. Zhang, H. Szpurka, and J. P. Maciejewski Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation Blood, February 1, 2008; 111(3): 1366 - 1377. [Abstract] [Full Text] [PDF] J. V. Melo and C. Chuah Novel Agents in CML Therapy: Tyrosine Kinase Inhibitors and Beyond Hematology, January 1, 2008; 2008(1): 427 - 435. [Abstract] [Full Text] [PDF] J. E. Cortes Imatinib and Beyond--Therapy of CML in 2008 ASCO Educational Book, January 1, 2008; 2008(1): 307 - 312. [Abstract] [Full Text] [PDF] A. Bergeron, D. Rea, V. Levy, C. Picard, V. Meignin, J. Tamburini, H. Bruzzoni-Giovanelli, F. Calvo, A. Tazi, and P. Rousselot Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia: A Case Series Am. J. Respir. Crit. Care Med., October 15, 2007; 176(8): 814 - 818. [Abstract] [Full Text] [PDF] J. M. Goldman How I treat chronic myeloid leukemia in the imatinib era Blood, October 15, 2007; 110(8): 2828 - 2837. [Abstract] [Full Text] [PDF] O. Ottmann, H. Dombret, G. Martinelli, B. Simonsson, F. Guilhot, R. A. Larson, G. Rege-Cambrin, J. Radich, A. Hochhaus, A. M. Apanovitch, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study Blood, October 1, 2007; 110(7): 2309 - 2315. [Abstract] [Full Text] [PDF] T. O'Hare, C. A. Eide, and M. W. N. Deininger Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia Blood, October 1, 2007; 110(7): 2242 - 2249. [Abstract] [Full Text] [PDF] R. D. Loberg, D. A. Bradley, S. A. Tomlins, A. M. Chinnaiyan, and K. J. Pienta The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy CA Cancer J Clin, July 1, 2007; 57(4): 225 - 241. [Abstract] [Full Text] [PDF] H. Kantarjian, R. Pasquini, N. Hamerschlak, P. Rousselot, J. Holowiecki, S. Jootar, T. Robak, N. Khoroshko, T. Masszi, A. Skotnicki, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial Blood, June 15, 2007; 109(12): 5143 - 5150. [Abstract] [Full Text] [PDF] A. Fabarius, C. Haferlach, M. C. Muller, P. Erben, T. Lahaye, M. Giehl, O. Frank, W. Seifarth, R. Hehlmann, and A. Hochhaus Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure Haematologica, June 1, 2007; 92(6): 834 - 837. [Abstract] [Full Text] [PDF] J. P. Radich The Biology of CML Blast Crisis Hematology, January 1, 2007; 2007(1): 384 - 391. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020